Fitzgerald Kevin Joseph (CIK 1886431) reported 137 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-04-09). Recent activity: Buy OVID (17,578 shares), Sell ALNY (210 shares), Sell ALNY (28 shares), Sell ALNY (59 shares), Sell ALNY (79 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-09 | Ovid Therapeutics Inc. (OVID) | Director | Buy | 17,578 | $45,000 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 210 | $68,006 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 28 | $8,960 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 59 | $18,928 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 79 | $25,424 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 96 | $31,009 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 29 | $9,252 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 75 | $24,366 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 57 | $18,563 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 124 | $39,904 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 233 | $75,317 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 148 | $48,041 |
| 2026-03-06 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 153 | $49,915 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Buy | 3,688 | $0 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 47 | $15,210 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 90 | $29,218 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 258 | $84,013 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 392 | $128,110 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 329 | $107,803 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 100 | $32,871 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 170 | $56,051 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 81 | $26,799 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 94 | $31,201 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 37 | $12,308 |
| 2026-03-04 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | CSO & EVP, Head of Research | Sell | 289 | $91,483 |
Source: SEC Form 4 filings · as of 2026-04-09